| Summary: | Embora o tratamento anti-retroviral (HAART highly active antiretroviral therapy) tenha reduzido a morbi-mortalidade da AIDS, ele está associado a distúrbios metabólicos e aumento do perfil de risco cardiovascular. Os escores de risco cardiovascular são freqüentemente usados para direcionar os programas de intervenções na redução do risco cardiovascular. O objetivo deste estudo é analisar o efeito de um programa de prevenção primária sobre o risco cardiovascular estimado por três diferentes escores de risco cardiovascular. Analisamos prospectivamente 87 pacientes HIV+ encaminhados ambulatório de cardiologia, com risco cardiovascular elevado. Foram aplicados três escores de risco cardiovascular: Framingham (FR), PROCAM (PR) e ATP III do NCEP (ATP-III) em 4 etapas: Inicial e trinta dias, três meses e seis meses após intervenção por meio de um programa de prevenção. Adotamos para este estudo o conceito de baixo risco os indivíduos que apresentaram valores dos escores abaixo de 10%, para as complicações cardiovasculares nos próximos 10 anos, e risco elevado se os valores dos escores fossem acima de 10%. Todos os pacientes receberam orientações para adoção de estilo de vida saudável (atividade física, combate ao tabagismo, uso de alimentos saudáveis) e terapêutica farmacológica, quando indicado (hipolipemiantes e anti-hipertensivos). A nossa população teve como média das idades 52 anos, 92% eram do sexo masculino, 39,1% tabagistas, 70,1% com hipertensão arterial sistêmica e 18,4% com diabetes mellitus. Todos os pacientes usaram HAART, e 56,3% faziam uso dos inibidores de protease, e nenhum paciente teve sua terapia trocada (switched). O perfil lipídico analisado na fase inicial apresentou os seguintes valores: triglicérides = 298,70 mg/dL ± 242,30 , colesterol total = 224,6 mg/dL ± 47,6 , LDL-colesterol = 129,50 mg/dL ± 44,50 , HDL-colesterol = 43,10 mg/dL ± 12,60. Seis meses após intervenção o perfil lipídico apresentou as seguintes alterações: triglicérides=206,20 mg/dL + 135.3 (p<0,05), colesterol total = 189.8 mg/dL + 38.0 (p<0,001), LDL-colesterol = 109.10 mg/dL + 30.30 (p<0,001), HDL-colesterol = 45.20 mg/dL + 13.30 (p=NS). Observamos uma redução da freqüência de indivíduos com risco cardiovascular elevado segundo o escore de FR, de 92,0% para 27,6% após a intervenção (p<0,0001), com escore ATP-III de 80,5% para 50,6% (p<0,0002) e com o escore PROCAM de 25,3% para 14,9%, (p=NS). O programa de intervenção proposto associou-se a uma redução do risco cardiovascular estimado. Todos os escores, com exceção do PROCAM mostraram-se úteis na prática clinica e para triagem e acompanhamento dos pacientes com risco cardiovascular elevado. Entretanto o escore de Framingham se mostrou como o mais sensível que os outros escores e detectou pequenas variações no risco cardiovascular em curto espaço de tempo, devendo este ser o escore de escolha para esta população === Although HAART therapy has reduced AIDS morbid-mortality, it is associated to metabolic disturbances and increased cardiac risk profile. It is well established in clinical cardiology that cardiac risk scores can predict cardiovascular complications with great accuracy and are useful to guide interventions toward risk reduction. We designed this study to analyze the effect of a primary prevention intervention program on the estimated cardiovascular risk and to compare the power of three different risk scores to detect risk reduction in a short time window. Methods: We prospectively evaluated 87 HIV + patients referred for cardiologic consultation for primary prevention and we assessed their cardiac risk applying 3 risk scores: Framingham (FR), PROCAM (PR) and National Cholesterol Education Program (ATP-III) in four steps: before and 30 days, 3 months and 6 months after intervention. For this study cardiovascular risk was classified as low if it was predicted less than 10% risk of cardiac complications for the next 10 years, or elevated, if it was higher than 10%. All patients were included in a cardiovascular prevention program and received non-pharmacological concealing (diet, physical activity prescription, smoking cessation advice) and pharmacological therapy, when appropriate (hypolipidemic and anti-hypertensive medications). Deviations in risk scores were compared using Fisher`s exact test at a p < .05 significance level. In our population, the mean age was 52 yrs, 92% were male, 39.1% were smokers, 70.1% had hypertension, 18.4% had diabetes. All patients were under HAART therapy, 56.3 % were receiving protease inhibitors, and no patient had his therapy switched. Lipid profile analysis before interventions revealed triglycerides = 298.70 mg/dL + 242.30, totalcholesterol= 224.6 mg/dL + 47.60, LDL-cholesterol = 129.50 mg/dL + 44.50, HDLcholesterol = 43.10 mg/dL + 12.60. Six months after intervention lipid profile change to: triglycerides = 206.20 mg/dL + 135.3 (p<.05), total-cholesterol = 189.8 mg/dL + 38.0 (p<.001), LDL-cholesterol = 109.10 mg/dL + 30.30 (p<.001), HDL-cholesterol = 45.20 mg/dL + 13.30 (p=NS). According to FR score, elevated cardiac risk before and 6 months after intervention was estimated in 92% x 27.6% of our patients, respectively (P = .0001). According to PROCAM score, it was 25.3% x 14.9%, respectively (P = NS). As for ATP-III, it was 80.5% x 50.6%, respectively (P= .0002). The proposed cardiovascular prevention program was associated with a reduction in the estimated cardiovascular risk in patients with HIV infection. All score risk indexes, except PROCAM are useful to the initial and follow-up evaluation of the cardiac risk in HIV infected patients, but the Framingham Risk score performance showed greater sensitivity than the others to detect small variations in a short time window, so it should be the score of choice
|
|---|
